Share
Publications
-
21 September 2006 /Product areas
Account of the blood product area in 2005
The account contains figures about the collection of blood from donors and the use of the blood collected. The account is published annually based on figures from blood centres and the Blood-donors in Denmark.
-
16 March 2006 /Prices and reimbursement
Changed consumption of hormones for menopausal women
The quantity consumption of hormones by women with menopausal discomfort has fallen drastically after announcements of increased risk of breast cancer. This is the finding of a consumption analysis performed by the Danish Medicines Agency on the basis of data from the Register of Medicinal Product Statistics.
-
12 October 2006 /Prices and reimbursement
Consumption of antibiotics 2000 – 2005
The past years' development of the consumption of antibiotics has shown that the consumption has increased greatly for several broad-spectrum products. The reason for this may be the increasing extent of prescriptions of broad-spectrum products for infections not requiring such treatment.
-
02 June 2006 /Prices and reimbursement
Consumption of benzodiazepines and benzodiazepine related drugs (cyclopyrrolones)
During the 4th quarter 2003 it was decided that a range of initiatives were to be launched with the purpose of maintaining and strengthening the current tendency of a total decreasing consumption of benzodiazepines (sleeping medicine, tranquilisers and anti-anxiety agents) as well as cyclopyrrolones.
-
29 August 2006 /About us
Danish Medicines Agency annual report 2005
The effort on ensuring consumer safety became very visible in the spring of 2005 when we decided to set up an individual division under this heading. Enhancing the safety of medicine users will also be the result of the new Medicines Act which entered into force in December.
-
23 February 2006 /Prices and reimbursement
Dose dispensing in the primary health sector - the last 6 months of 2005
During the first 6 months of 2005, approximately 26.000 people had their medicinal products dose dispensed. Elderly women constitute the main part of this group. The consumption of dose dispensed medicinal products amounts to 1.6 per cent of the total consumption of medicinal products during the first 6 months of 2005.
-
31 July 2006 /Prices and reimbursement
Examination of single reimbursement for medicinal products
On behalf of Merck Sharp & Dohme (MSD), Tranberg Marketing Rekommandation has examined general practitioners' knowledge, experience and attitude to single reimbursement for medicine ("Praktiserende lægers kendskab, erfaring og holdning til enkelttilskud til medicin"). The examination is based on telephone interviews with 282 general practitioners.
-
06 June 2006 /Prices and reimbursement
-
15 November 2006 /Authorisation and supervision
Product defects and withdrawal of medicinal products in 2005
In 2005, there was almost the same number of reports on product defects as in 2004. The reports comprised both marketed and non-marketed medicinal products, including magistral medicinal products, which are manufactured according to a doctor's prescription.
-
21 March 2006 /Side effects and trials
Report assessing the EU system monitoring medicinal product safety
In 2004, the EU Commission decided to launch an assessment of the existing system for monitoring of medicinal products, primarily to enable an assessment of the need for potential and possible improvements.
-
22 December 2006 /Retail and online sale
Report on action against the sale of illegal medicinal products on the internet
In November/December 2006, the Danish Medicines Agency carried out an internet action against the illegal sale of medicinal products over the internet. The action primarily focused on potency and diet products.
-
13 December 2006 /Publications - miscellaneous
Report on generic prescription – advantages and disadvantages
The aim of this report is to analyse and describe the advantages and disadvantages related to generic prescription. The report is based on a Swedish report on generic prescription ("Generisk förskrivning"), which was drawn up by the Swedish Medicinal Products Agency. Moreover, the report is based on views and comments from external interested parties as well as on a brief review of the conditions in a number of European countries.
